Article
Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer.
Molecular medicine (Cambridge, Mass.) - 8 Feb 2013
Dono Mariella, Massucco Carlotta, Chiara Silvana, Sonaglio Claudia, Mora Marco, Truini Anna, Cerruti Giannamaria, Zoppoli Gabriele, Ballestrero Alberto, Truini Mauro, Ferrarini Manlio, Zupo Simona
Abstract excerpt
Metastatic colorectal cancer (mCRC) is frequently characterized by the presence of mutations of the KRAS oncogene, which are generally associated with a poor response to treatment with anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies. With the methods currently used, a case is classified as KRAS-mutated when approximately 20% of the cells bear an activating KRAS mutation. These...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.